Masoprocolum [INN-Latin] en es it fr

Masoprocolum [INN-Latin] Brand names, Masoprocolum [INN-Latin] Analogs

Masoprocolum [INN-Latin] Brand Names Mixture

  • No information avaliable

Masoprocolum [INN-Latin] Chemical_Formula


Masoprocolum [INN-Latin] RX_link

Masoprocolum [INN-Latin] fda sheet

Masoprocolum_[INN-Latin] FDA

Masoprocolum [INN-Latin] msds (material safety sheet)

Masoprocolum_[INN-Latin] MSDS

Masoprocolum [INN-Latin] Synthesis Reference

No information avaliable

Masoprocolum [INN-Latin] Molecular Weight

342.472 g/mol

Masoprocolum [INN-Latin] Melting Point


Masoprocolum [INN-Latin] H2O Solubility

2 µg/mL (at 37°C for the acetate salt)

Masoprocolum [INN-Latin] State


Masoprocolum [INN-Latin] LogP


Masoprocolum [INN-Latin] Dosage Forms

Oral suspension containing 125 mg of megestrol acetate per mL; Tablet

Masoprocolum [INN-Latin] Indication

For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used to treat breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries.

Masoprocolum [INN-Latin] Pharmacology

Megestrol is a synthetic progestin and has the same physiologic effects as natural progesterone. The precise mechanism of megestrol’s antianorexic and anticachetic effects is unknown. Initially developed as a contraceptive, it was first evaluated in breast cancer treatment in 1967.

Masoprocolum [INN-Latin] Absorption

Variable, but well absorbed orally.

Masoprocolum [INN-Latin] side effects and Toxicity

No serious unexpected side effects have resulted from studies involving megestrol acetate oral suspension administered in dosages as high as 1200 mg/day.

Masoprocolum [INN-Latin] Patient Information

No information avaliable

Masoprocolum [INN-Latin] Organisms Affected

Humans and other mammals